Using Nanomedicine to Drive Advances in Cancer Immunotherapy: A Mini Review |Biomedgrid

Immunotherapy has shown remarkable clinical success and holds tremendous promise for enhancing cancer treatment Outcome. However, therapeutic complete responses are limited to a subset of patients selected cancers and treatment outcome can trigger severe toxicity due to systemic activation of the immune system. Here, we discuss the opportunities to overcome these drawbacks by combining immunotherapy with nanomedicine using tailor-made nanoparticles (NPs) to increase cancer selectivity and minimize toxicity. Further, we provide directions on requirements and discuss advantageous characteristics of using calcium carbonate as core component of such NPs.